Prosecution Insights
Last updated: November 04, 2026
Application No. 19/011,047

Solid Dosage Form

Non-Final OA §103§112§DOUBLEPATENT
Filed
Jan 06, 2025
Priority
Oct 30, 2009 — SG 200907221-6 +8 more
Examiner
LIU, TRACY
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ix Biopharma Ltd.
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
1y 4m
Est. Remaining
81%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
374 granted / 689 resolved
-5.7% vs TC avg
Strong +26% interview lift
Without
With
+26.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
85 currently pending
Career history
794
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
49.0%
+9.0% vs TC avg
§102
4.5%
-35.5% vs TC avg
§112
25.0%
-15.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 689 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Claims included in the prosecution are claims 28-35. Claim Objections Claim 34 is objected to because of the following informalities: “and” should be recited immediately prior to “benzocaine” in the last line. Appropriate correction is required. Claim 35 is objected to because of the following informalities: “and” should be recited immediately prior to “gamma interferon.” Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 28-35 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 28 recites wherein the biologically active material is “selected from the list comprising.” The claim is indefinite since the Markush grouping requires a material selected from an open list of alternatives and it is unclear what other alternatives are intended to be encompassed by the claim. See MPEP 2173.05(h). Claim 29 recites in part ii) “or analgesic and anti-inflammatory agents.” The claim is indefinite since it is unclear whether the claim requires all the species in part ii) or requires only one of the species in part ii). Claim 29 is further indefinite since the claim does not recite the term “or” or “and” after the limitation of part iii). It is unclear whether the claim requires the limitations of i), ii), iii) and iv) or whether the claim requires the limitations of one of i), ii), iii) or iv). If the claim requires the limitations of i), ii), iii) and iv), the claim is additionally indefinite since some active materials are recited in multiple parts with different amounts, thus, it is unclear how much active material the composition contains. For example, anti-arrhythimic agent is recited in part iii) in an amount of 5 to 50 weight % and is recited in part iv) in an amount of 0.02 to 50 weight %. For sake of compact prosecution, the Examiner has interpreted claim 29 to require the limitations of one of i), ii), iii) or iv). Claim 34 recites wherein the biologically active material is “selected from the list comprising.” The claim is indefinite since the Markush grouping requires a material selected from an open list of alternatives and it is unclear what other alternatives are intended to be encompassed by the claim. See MPEP 2173.05(h). Claim 35 recites wherein the interferon is “selected from the list comprising.” The claim is indefinite since the Markush grouping requires a material selected from an open list of alternatives and it is unclear what other alternatives are intended to be encompassed by the claim. See MPEP 2173.05(h). Claim Rejections - 35 USC § 103 The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under pre-AIA 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 1. Claims 28, 29 and 32-34 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Patel et al. (WO 2007/034287 A2, Mar. 29, 2007) (hereinafter Patel) in view of Singh et al. (US 2005/0208110, Sep. 22, 2005) (hereinafter Singh), as evidenced by Park et al. (WO 01/037814, May 31, 2001) (hereinafter Park). Patel discloses a freeze-dried oramucosal pharmaceutical dosage form in the form of a wafer. The wafer comprises a porous, hydroscopic, muco-adhesive polymeric matrix with at least one desired pharmaceutically active compound added thereto. The polymer is selected from a number of polymers having different dissolution rates and, in use when taken orally, the matrix adheres to an oramucosal surface to dissolve over a predetermined period of time to release the pharmaceutically active compound (abstract). The polymers may be mixed with excipients such as glycine, mannitol, or lactose, which alters the physiochemical and/or pysicomechanical properties of the polymer (page 4, lines 6-9). Suitable excipient and polymer combinations allow for the development of rapidly disintegrating and prolonged release wafer systems. Wafer systems containing HPC, lactose, mannitol, and glycine had the ability to disintegrate within 30 seconds (page 14, lines 12-15). It was generally noted that higher polymer concentrations were associated with lower rates of disintegration. Due the highly soluble nature of diluents, an increase in the amount accounted for higher matrix solubility and thus faster rates of disintegration (page 10, lines 4-7). Mannitol, lactose and glycine are diluents (Table 1 and Figure 6). The dosage form may comprise mannitol, lactose, and glycine (Table 1). Suitable pharmaceutically active compounds include sedatives (page 4, line 30) and antihistamines, such as loratadine (i.e., histamine H-receptor antagonist) (page 5, line 1). Patel differs from the instant claims insofar as not teaching wherein the dosage form comprises amylopectin. However, Singh discloses a rapidly dissolving film for delivery of an active agent to a moist body surface. The film comprises a rapidly dissolving polymeric material (abstract). Suitable rapidly dissolving polymeric materials include amylopectin (¶ [0048]). Suitable moist body surface includes the surfaces in and around the oral cavity (¶ [0028]). The term “rapidly” is intended to mean that the film dissolves in less than about 10 minutes after application, preferably within about 5 seconds to 10 minutes after application. The film is designed to release the active agent within the time frame of the dissolution of the film (¶ [0037]). Accordingly, it would have been prima facie obvious to one of ordinary skill in the art to have incorporated amylopectin into the dosage form of Patel since the dosage form comprises a number of polymers having different dissolution rates and amylopectin is a known rapidly dissolving polymer for oral compositions as taught by Singh. Regarding the amount of amylopectin claimed, as discussed above, Patel discloses wherein polymer concentration affects disintegration. Therefore, since amylopectin is a rapidly dissolving polymer, it would have taken no more than the relative skills of one of ordinary skill in the art through routine experimentation to have arrived at the claimed amount of amylopectin depending on the rate of disintegration desired for the dosage form. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. See MPEP 2144.05(II)(A). Regarding the amount of biologically active material (e.g., histamine H-receptor antagonist) claimed, Patel discloses wherein loratadine is an antihistamine. Accordingly, it would have taken no more than the relative skills of one of ordinary skill in the art through routine experimentation to have arrived at the claimed amount of loratadine (i.e. histamine H-receptor antagonists) depending on the level of antihistamine effect desired. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. See MPEP 2144.05(II)(A). Regarding the amount of mannitol and glycine claimed, Patel discloses wherein mannitol and glycine are diluents and wherein the amount of diluents affect rates of disintegration. Accordingly, it would have taken no more than the relative skills of one of ordinary skill in the art through routine experimentation to have arrived at the claimed amount of mannitol and glycine depending on the rate of disintegration desired for the dosage form. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. See MPEP 2144.05(II)(A). Regarding instant claim 28 reciting wherein said biologically active material is absorbed by diffusion directly into the systemic circulation, as evidenced by Park, when an oral composition comprising an active compound is contacted with saliva and disintegrates, the active compound is absorbed through the oral mucosa and into the systemic circulation (page 4, lines 27-31). Therefore, since Patel discloses wherein the dosage form disintegrates in the oral cavity and the pharmaceutically active compound is released, the pharmaceutically active compound of Patel would be absorbed by diffusion directly into the systemic circulation. Regarding instant claims 28 reciting wherein the amylopectin is not in the form of starch or modified starch, Singh does not disclose wherein the amylopectin is in the form of starch or modified starch. Regarding the amount of sedative claimed in instant claim 29, as discussed above, Patel discloses wherein the composition may comprise sedatives. It would have taken no more than the relative skills of one of ordinary skill in the art through routine experimentation to have arrived at the claimed amount of sedatives depending on the level of sedation desired. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. See MPEP 2144.05(II)(A). 2. Claims 30 and 31 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Patel et al. (WO 2007/034287 A2, Mar. 29, 2007) (hereinafter Patel) in view of Singh et al. (US 2005/0208110, Sep. 22, 2005) (hereinafter Singh), and further in view of Gole et al. (US 5,558,880, Sep. 24, 1996) (hereinafter Gole), as evidenced by Park et al. (WO 01/037814, May 31, 2001) (hereinafter Park). The teachings of Patel and Singh are discussed above. Patel and Singh do not teach wherein the dosage form comprises microcrystalline cellulose. However, Gole discloses a solid dosage form comprising a porous network of matrix material that disperses rapidly in water (col. 2, lines 43-44). The speed in which the dosage form dissolved is dependent in large part on the choice of matrix forming agent(s) and their concentration (col. 6, lines 43-45). Suitable matrix forming materials include microcrystalline cellulose (col. 6, line 52). Accordingly, it would have been prima facie obvious to one of ordinary skill in the art to have incorporated microcrystalline cellulose into the dosage form of Patel since the dosage form comprises a number of polymers having different dissolution rates and microcrystalline cellulose is a known and effective polymer for oral compositions having a dissolution rate as taught by Gole. Regarding the amount of microcrystalline cellulose claimed, as discussed above, Patel discloses wherein polymer concentration affects disintegration. Therefore, since microcrystalline cellulose is a dissolvable polymer, it would have taken no more than the relative skills of one of ordinary skill in the art through routine experimentation to have arrived at the claimed amount of microcrystalline cellulose depending on the rate of disintegration desired for the dosage form. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. See MPEP 2144.05(II)(A). 3. Claim 35 is rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Patel et al. (WO 2007/034287 A2, Mar. 29, 2007) (hereinafter Patel) in view of Singh et al. (US 2005/0208110, Sep. 22, 2005) (hereinafter Singh), and further in view of Houghton et al. (US 2004/0228919, Nov. 18, 2004) (hereinafter Houghton), as evidenced by Park et al. (WO 01/037814, May 31, 2001) (hereinafter Park). The teachings of Patel and Singh are discussed above. Patel and Singh do not teach wherein the dosage form comprises alpha-2 interferon. However, Houghton discloses a non-compressed fast-dispersing solid dosage form suitable for oromucosal administration of a pharmaceutically active substance comprising an active substance (abstract). Suitable active substances include proteins, peptides, and recombinant drugs such as alpha-2 interferon for the treatment of common cold (¶ [0131]). Generally, it is prima facie obvious to select a known material for incorporation into a composition, based on its recognized suitability for its intended use. See MPEP 2144.07. Patel discloses wherein the dosage form comprises a pharmaceutically active compound. Accordingly, it would have been prima facie obvious to one of ordinary skill in the art to have incorporated alpha-2 interferon into the dosage form of Patel since it is a known and effective pharmaceutically active compound for oromucosal dosage forms and it treats common cold should that be desired as taught by Houghton et al. Regarding the amount of alpha-2 interferon, as discussed above, alpha-2 interferon treats common cold. Accordingly, it would have taken no more than the relative skills of one of ordinary skill in the art through routine experimentation to have arrived at the claimed amount of alpha-2 interferon depending on the level of treatment for the common cold desired. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. See MPEP 2144.05(II)(A). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 28-35 are rejected on the ground of nonstatutory double patenting as being unpatentable over the claims of U.S. Patent Nos. 10,744,086, 11,975,097, and 12,186,426. Although the claims at issue are not identical, they are not patentably distinct from each other because the conflicting claims recite a more specific version of the instant claims (i.e., the conflicting claims recite additional limitations, such as the powder x-ray diffraction (XRD) of the dosage form) and thus read on the instant claims. Claims 28-35 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 10,857,097. Although the claims at issue are not identical, they are not patentably distinct from each other because the pending claims and patented claims both recite a fast disintegrating and dissolving freeze-dried wafer comprising a biologically active material, amylopectin, and a carbohydrate. The pending claims differ from the patented claims insofar as reciting an amount of biologically active material. However, it would have taken no more than the relative skills of one of ordinary skill in the art to have arrived ta the claimed amount of biologically active material depending on the therapeutic effect desired. Conclusion Claims 28-35 are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TRACY LIU whose telephone number is (571)270-5115. The examiner can normally be reached Mon-Fri 9 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TRACY LIU/ Primary Examiner, Art Unit 1614
Read full office action

Prosecution Timeline

Jan 06, 2025
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778871
COSMETIC COMPOSITION COMPRISING A COMBINATION OF TWO PARTICULAR COUPLERS AND N,N-DICARBOXYMETHYLGLUTAMIC ACID AND/OR ITS SALTS
3y 4m to grant Granted Nov 03, 2026
Patent 12767888
PREPARATION METHOD FOR DEGRADABLE LIQUID-STATE MULCHING FILM BY USING LIVESTOCK MANURE AS RAW MATERIAL
2y 2m to grant Granted Oct 20, 2026
Patent 12714656
AQUEOUS ORAL CARE IODIDE-CONTAINING COMPOSITIONS, METHODS, AND KITS
2y 11m to grant Granted Aug 25, 2026
Patent 12636246
PROCESS FOR COLOURING HAIR KERATIN FIBERS, COMPRISING THE APPLICATION OF A COMPOSITION COMPRISING AT LEAST ONE (POLY)CARBODIIMIDE COMPOUND AND A COMPOSITION COMPRISING AT LEAST ONE ASSOCIATIVE POLYMER AND A PARTICULAR COMPOUND
2y 8m to grant Granted May 26, 2026
Patent 12605314
BROAD-SPECTRUM, MINERAL, PHOTOPROTECTIVE COMPOSITIONS
2y 9m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
81%
With Interview (+26.4%)
3y 2m (~1y 4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 689 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month